Navigation Links
Allergan's Global Dominance in Facial Injectables Challenged by Acquisitions and Partnership Agreements Among Competitors
Date:5/14/2013

TORONTO, May 14, 2013 /PRNewswire/ -- According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, Allergan continues to dominate the global facial injectable market but is facing increasing competition from a growing number of competitors. As the traditional leader in this market, Allergan earned its top position primarily through its longstanding monopoly of the global botulinum toxin (BTX) market, where its BOTOX Cosmetic product has become commonly considered synonymous with BTX itself. In recent years, however, more competitors have entered the BTX market, and the newer market for dermal fillers has also blossomed, making it difficult for Allergan to maintain its share.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36799LOGO )

This is especially true given the number of acquisitions and partnership agreements that have occurred in the facial injectable market. For example, Q-Med, which manufactured the popular and original hyaluronic acid (HA) dermal filler, Restylane, was acquired by Galderma in mid-2011. Given that Galderma already distributed Ipsen's Dysport BTX product in a number of geographies, the company can now offer both products together, competing with Allergan's product bundle of BOTOX Cosmetic and its popular JUVEDERM dermal filler.

Sanofi also sold its Dermik Laboratories subsidiary to Valeant Pharmaceuticals International around the same time, passing on the ownership of Dermik's popular line of Sculptra Aesthetic non-HA dermal fillers. More recently, Valeant Pharmaceuticals International acquired Medicis, which distributes Restylane and Dysport in North America. This allows Valeant Pharmaceuticals to become a major competitor in the lucrative North American market, where it will offer products across all three facial injectable product categories.

"Valeant Pharmaceuticals International, Ipsen and Galderma aren't Allergan's only problems," said MRG Senior Analyst Karen Gierszewski . "The injunction Allergan won against Merz Pharma in the United States was lifted early this year, and all signs point to XEOMIN earning rapid adoption in the country. Additionally, Allergan has historically struggled in the Asia Pacific BTX market, where low-cost local competitors such as Medytox, Lanzhou Institute of Biological Products (LIBP) and Hugel continue to be very successful."

Millennium Research Group's Global Competitor Insights for Facial Injectables 2013 report includes an overview of the global facial injectable market as well as detailed insight on the top ten manufacturers in this space. The geographies included in this analysis are North America (United States and Canada), Europe (France, Germany, Italy, Spain and the United Kingdom) and the Asia Pacific (Australasia, China, South Korea and Japan).

About Millennium Research Group
Millennium Research Group (www.MRG.net), a Decision Resources Group company (www.DecisionResourcesGroup.com), is the global authority on medical technology market intelligence and the leading provider of strategic information to the healthcare sector. The company provides specialized industry expertise through multiclient market research, ongoing Marketrack™ projects, customer loyalty tracking, facility-level procedure forecasting, and customized solutions.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information, and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:


Christopher Comfort
Decision Resources Group
781-993-2597
ccomfort@dresources.com

Alex Jablokow
Millennium Research Group
617-599-8613
ajablokow@mrg.net


'/>"/>
SOURCE Millennium Research Group
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Top buyers including Atico, Coles Group Asia, Kmart, Staples, Office Depot and Target Australia pre-registered to attend Global Sources spring China Sourcing Fairs
2. ConvaTec Donates $10,000 To AAWC Global Volunteers Program Through SAWC Walk For Wellness
3. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
4. Attendees Save Up To $800 on Global Healthcare Conferences in 2012 by Registering Through Global Information Inc.
5. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
6. Varian Medical Systems and Siemens Healthcare Announce Global Collaboration to Advance Clinical Capabilities and Offerings in Radiotherapy and Radiosurgery
7. Ultra Clean to Present at the Jefferies 2012 Global Technology, Media & Telcom Conference
8. Axis Global Logistics Names Mr. Thomas Brennan, Vice President Strategic Accounts & Life Sciences
9. Angeion Appoints Matthew S. Margolies as Executive Vice President - Global Sales
10. OTC Pharmaceuticals: Global Industry Almanac, MarketLine
11. Global Pharmaceutical Leaders All Converging in Parsippany, New Jersey on September 11-12, 2012 for Breakthrough Event
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... One of Australia,s successful biotechnology ... a new biotechnology company, Noxopharm Limited [ABN 50 608 966 123] ... to list on the ASX. Noxopharm is a clinic-ready ... a Phase 1 clinical study later this year. ... the biggest problems facing cancer patients - the ability of cancers ...
(Date:6/26/2016)... Jazz Pharmaceuticals plc (Nasdaq: JAZZ ... Antitrust Improvements Act of 1976, as amended ("HSR"), with ... ("Celator"; Nasdaq: CPXX ) expired effective June ... As previously announced on May 31, 2016, Jazz ... under which Jazz Pharmaceuticals has commenced a tender offer ...
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, Inc. ... will take whatever measures required to build a strong ... which is currently listed on the OTC Markets-pink current ... Chairman and CEO, "We are seeing an anomaly in ... understand, not only by the Company, but shareholders and ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are confused ... endometriosis. These women need a treatment plan to not only alleviate symptoms and ... help for preservation of fertility and ultimately achieving a pregnancy. The specialists at ...
(Date:6/25/2016)... ... 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due to ... a new, often overlooked aspect of head lice: the parasite’s ability to live away from ... common occurrence, but a necessary one in the event that lice have simply gotten out ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... As a ... Magna Cum Laude and his M.D from the David Geffen School of Medicine at ... returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits ... terms of the latter, setting the bar too high can result in disappointment, perhaps ... slow progress toward their goal. , Research from PsychTests.com reveals that ...
(Date:6/24/2016)... ... , ... June 19, 2016 is World Sickle Cell Observance Day. In an ... of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a ... Cell Disease (SCD) is a disorder of the red blood cells, which can cause ...
Breaking Medicine News(10 mins):